Spots Global Cancer Trial Database for Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

Official Title: Efficacy and Safety of Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitor

Study ID: NCT03590808

Conditions

Influenza

Solid Carcinoma

Interventions

Influenza vaccination

Study Description

Brief Summary: The purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer patients receiving immune checkpoint inhibitor.

Detailed Description: * Solid cancer patients receiving immune checkpoint inhibitor or cytotoxic chemotherapy will be recruited 1:2 manner in two hospitals. Target numbers are 48 and 95, respectively. * All the participants will be vaccinated for influenza during their chemotherapy when they meet inclusion criteria. * All the participants will be asked if they have any contraindication for influenza vaccine by a physician before vaccination. * Hemagglutination inhibition Ab titre at pre-vaccination and post-vaccination (21-35 days after vaccination) will be examined in all participants to examine seroprotection rates, seroconversion rates, and changes in geometric mean titer. * And they will be monitored for any vaccination-related adverse reaction or immune-related adverse events after 2-4 days(via phone call), and till 6 months after vaccination (when they visit oncology clinics).